<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01223183</url>
  </required_header>
  <id_info>
    <org_study_id>PRO09080375</org_study_id>
    <nct_id>NCT01223183</nct_id>
  </id_info>
  <brief_title>Absorptive Clearance After Inhaled Osmotics in Cystic Fibrosis</brief_title>
  <official_title>Absorptive Clearance After Inhaled Osmotics in Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Blockage of the breathing tubes of the lungs by thick, sticky mucus is a major cause of lung
      problems for people with cystic fibrosis (CF). Many researchers now believe that people with
      CF absorb too much water from the insides of their lungs, and that the mucus in their lungs
      becomes so thick and sticky because there is not enough water in it. The investigators are
      trying to develop ways to measure how fast water is absorbed from the breathing tubes in the
      lung so that the investigators can more quickly test new medications that are being developed
      to fix this problem for CF patients. The investigators have already done studies showing that
      people with CF absorb a particular radioactive drug (Indium-111 diethylenetriaminepentaacetic
      acid or In-DTPA) from their lungs more quickly than people without CF. Now the investigators
      are trying to prove that the absorption of this drug is related to the absorption of water.
      The investigators measure the absorption of In-DTPA by delivering it in an aerosol (inhaled
      mist) along with another radioactive drug (Technetium 99m sulfur colloid or Tc-SC). This
      other drug helps us measure how much material is cleared from the lungs in other ways (like
      coughing) without being absorbed. In this study, the investigators will measure how the
      absorption of In-DTPA is affected by inhaling isotonic saline and hypertonic saline (salt
      water), both of which the investigators know affect the absorption of water in the airways.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a substantial need for new biomarkers in the study of cystic fibrosis (CF) lung
      disease. Conventional endpoints, such as rate of FEV1 decline, require prolonged trials and
      large sample sizes to demonstrate therapeutic efficacy. Ideally such biomarkers would provide
      a quantitative window to the most basic aspects of CF pathophysiology, allowing for the
      development and evaluation of therapies prior to large scale clinical trials. The basic
      defect of CF lung disease occurs in the airways where dysfunction of the cystic fibrosis
      transmembrane conductance regulator (CFTR) and epithelial sodium (ENaC) channels is thought
      to create an ionic gradient that causes excessive liquid absorption across the epithelium.
      This results in a dehydrated airway surface liquid (ASL) layer, defective mucociliary
      clearance, and an increased proclivity for infection and inflammation.

      Aerosol-based methods have been developed to measure mucociliary clearance in the lung and
      used to demonstrate the efficacy of inhaled osmotic therapies. We have developed an aerosol
      technique to measure both mucociliary clearance and the absorptive clearance of a hydrophilic
      small molecule (diethylenetriaminepentaacetic acid or DTPA) in whole, central, and peripheral
      lung regions. We estimate DTPA absorption by delivering an aerosol containing both Indium 111
      DTPA (In-DTPA) and Technetium 99m sulfur colloid (Tc-SC) to the airways. The clearance of
      each radiopharmaceutical is imaged independently and two separate clearance curves are
      calculated. In-DTPA is cleared through both absorption and mucociliary clearance while Tc-SC
      is cleared only through the mucociliary route. The difference between the clearance rates of
      the radiopharmaceuticals provides an estimate of In-DTPA absorption rate.

      Our previous studies have demonstrated that absorption of In-DTPA occurs at a higher rate in
      central (airway dominated) lung zones of CF subjects compared to controls (42 vs. 32 %/hr, CF
      n= 9, control n=10, p=0.03). We believe that this increased In-DTPA absorption is being
      caused by the increased liquid absorption occurring in these airways, however there are other
      potential causes such as increase in tight junction permeability or epithelial denuding.

      In this study we propose to measure In-DTPA absorption after the delivery of interventions
      known to affect liquid absorption in the airways to see if changes in In-DTPA absorption
      mirror the changes in liquid absorption known to be caused by the interventions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Subjects inhale isotonic saline on one imaging day and 7% hypertonic on the other. The order is randomized. There is a period of 5-24 days between imaging days.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absorptive Clearance Rate After Isotonic Saline Inhalation</measure>
    <time_frame>80 minutes after radiopharmaceutical inhalation</time_frame>
    <description>The absorption rate of Indium 111 diethylenetriaminepentaacetic acid (In-DTPA) in the airways after the inhalation of isotonic saline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absorptive Clearance Rate After Hypertonic Saline Inhalation</measure>
    <time_frame>80 minutes after radiopharmaceutical inhalation</time_frame>
    <description>The absorption rate of In-DTPA after the inhalation of hypertonic saline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mucociliary Clearance Rate After Isotonic Saline Inhalation</measure>
    <time_frame>80 minutes after radiopharmaceutical inhalation</time_frame>
    <description>The clearance rate of Tc-SC after the inhalation of isotonic saline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mucociliary Clearance Rate After Hypertonic Saline Inhalation</measure>
    <time_frame>80 minutes after radiopharmaceutical inhalation</time_frame>
    <description>The clearance rate of Tc-SC after the inhalation of hypertonic saline</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>isotonic saline then hypertonic saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects inhaled nebulized isotonic saline on study day 1, and then after a 5-24 day washout period, subjects inhaled nebulized 7% hypertonic saline on study day 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hypertonic saline then isotonic saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects inhaled nebulized 7% hypertonic saline on study day 1, and then after a 5-24 day washout period, subjects inhaled nebulized isotonic saline on study day 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hypertonic saline (7%)</intervention_name>
    <description>single treatment by inhalation</description>
    <arm_group_label>isotonic saline then hypertonic saline</arm_group_label>
    <arm_group_label>hypertonic saline then isotonic saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isotonic saline</intervention_name>
    <description>single treatment by inhalation</description>
    <arm_group_label>isotonic saline then hypertonic saline</arm_group_label>
    <arm_group_label>hypertonic saline then isotonic saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age â‰¥ 18 years

          -  diagnosis of cystic fibrosis as determined by sweat test or genotype and clinical
             symptoms

          -  clinically stable as determined by the investigator (pulmonologist)

        Exclusion Criteria:

          -  intolerant to hypertonic saline.

          -  FEV1%p &lt;40% of predicted

          -  nursing mother

          -  positive urine pregnancy test

          -  unwilling to stop hypertonic saline therapy for 72 hours prior to each test day

          -  cigarette smoker (regular smoking within 6 months of study)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Corcoran, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.dom.pitt.edu/paccm/faculty_info.aspx/Corcoran5127</url>
    <description>PACCM aerosol research</description>
  </link>
  <reference>
    <citation>Corcoran TE, Thomas KM, Myerburg MM, Muthukrishnan A, Weber L, Frizzell R, Pilewski JM. Absorptive clearance of DTPA as an aerosol-based biomarker in the cystic fibrosis airway. Eur Respir J. 2010 Apr;35(4):781-6. doi: 10.1183/09031936.00059009. Epub 2009 Aug 28.</citation>
    <PMID>19717485</PMID>
  </reference>
  <results_reference>
    <citation>Locke LW, Myerburg MM, Markovetz MR, Parker RS, Weber L, Czachowski MR, Harding TJ, Brown SL, Nero JA, Pilewski JM, Corcoran TE. Quantitative imaging of airway liquid absorption in cystic fibrosis. Eur Respir J. 2014 Sep;44(3):675-84. doi: 10.1183/09031936.00220513. Epub 2014 Apr 17.</citation>
    <PMID>24743971</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2010</study_first_submitted>
  <study_first_submitted_qc>October 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2010</study_first_posted>
  <results_first_submitted>April 5, 2017</results_first_submitted>
  <results_first_submitted_qc>July 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 5, 2018</results_first_posted>
  <last_update_submitted>July 24, 2017</last_update_submitted>
  <last_update_submitted_qc>July 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Tim Corcoran</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>cystic fibrosis</keyword>
  <keyword>nuclear medicine</keyword>
  <keyword>aerosol</keyword>
  <keyword>nebulizer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Isotonic Saline Then Hypertonic Saline</title>
          <description>Subjects inhale nebulized isotonic saline on study day 1, then perform a washout period of 5-24 days, then inhale 7% hypertonic saline on study day 2.</description>
        </group>
        <group group_id="P2">
          <title>Hypertonic Saline Then Isotonic Saline</title>
          <description>Subjects inhale nebulized 7% hypertonic saline on study day 1, then perform a 5-24 day washout period, and then inhale nebulized isotonic saline on study day 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Imaging Day 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period (5-24 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Imaging Day 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Isotonic Saline Then Hypertonic Saline</title>
          <description>Subjects inhaled isotonic saline on study day 1, then had a washout period of 5-24 days, then inhaled 7% hypertonic saline on study day 2</description>
        </group>
        <group group_id="B2">
          <title>Hypertonic Saline Then Isotonic Saline</title>
          <description>Subjects inhaled 7% hypertonic saline on study day 1, then had a washout period of 5-24 days, then inhaled isotonic saline on study day 2</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" spread="11"/>
                    <measurement group_id="B2" value="24" spread="5"/>
                    <measurement group_id="B3" value="26" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absorptive Clearance Rate After Isotonic Saline Inhalation</title>
        <description>The absorption rate of Indium 111 diethylenetriaminepentaacetic acid (In-DTPA) in the airways after the inhalation of isotonic saline</description>
        <time_frame>80 minutes after radiopharmaceutical inhalation</time_frame>
        <population>This group includes data from the isotonic saline inhalation day from both the &quot;isotonic then hypertonic&quot; and the &quot;hypertonic than isotonic&quot; groups who had sufficient imaging data to allow for full analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Isotonic Saline Inhalation</title>
            <description>Results from isotonic inhalation day</description>
          </group>
        </group_list>
        <measure>
          <title>Absorptive Clearance Rate After Isotonic Saline Inhalation</title>
          <description>The absorption rate of Indium 111 diethylenetriaminepentaacetic acid (In-DTPA) in the airways after the inhalation of isotonic saline</description>
          <population>This group includes data from the isotonic saline inhalation day from both the &quot;isotonic then hypertonic&quot; and the &quot;hypertonic than isotonic&quot; groups who had sufficient imaging data to allow for full analysis.</population>
          <units>percent / 80 minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Absorptive Clearance Rate After Hypertonic Saline Inhalation</title>
        <description>The absorption rate of In-DTPA after the inhalation of hypertonic saline</description>
        <time_frame>80 minutes after radiopharmaceutical inhalation</time_frame>
        <population>This group includes data from the hypertonic saline inhalation day from both the &quot;isotonic then hypertonic&quot; and the &quot;hypertonic than isotonic&quot; groups who had sufficient imaging data to allow for full analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Hypertonic Saline Inhalation</title>
            <description>Results from hypertonic saline inhalation day</description>
          </group>
        </group_list>
        <measure>
          <title>Absorptive Clearance Rate After Hypertonic Saline Inhalation</title>
          <description>The absorption rate of In-DTPA after the inhalation of hypertonic saline</description>
          <population>This group includes data from the hypertonic saline inhalation day from both the &quot;isotonic then hypertonic&quot; and the &quot;hypertonic than isotonic&quot; groups who had sufficient imaging data to allow for full analysis.</population>
          <units>percent cleared / 80 minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparing DTPA absorption after hypertonic saline inhalation to DTPA absorption after isotonic saline inhalation</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>alpha=0.05</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mucociliary Clearance Rate After Isotonic Saline Inhalation</title>
        <description>The clearance rate of Tc-SC after the inhalation of isotonic saline</description>
        <time_frame>80 minutes after radiopharmaceutical inhalation</time_frame>
        <population>This group includes data from the isotonic saline inhalation day from both the &quot;isotonic then hypertonic&quot; and the &quot;hypertonic than isotonic&quot; groups who had sufficient imaging data to allow for full analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Isotonic Saline Inhalation</title>
            <description>Results from isotonic saline inhalation day</description>
          </group>
        </group_list>
        <measure>
          <title>Mucociliary Clearance Rate After Isotonic Saline Inhalation</title>
          <description>The clearance rate of Tc-SC after the inhalation of isotonic saline</description>
          <population>This group includes data from the isotonic saline inhalation day from both the &quot;isotonic then hypertonic&quot; and the &quot;hypertonic than isotonic&quot; groups who had sufficient imaging data to allow for full analysis.</population>
          <units>percent cleared / 80 minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.6" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mucociliary Clearance Rate After Hypertonic Saline Inhalation</title>
        <description>The clearance rate of Tc-SC after the inhalation of hypertonic saline</description>
        <time_frame>80 minutes after radiopharmaceutical inhalation</time_frame>
        <population>This group includes data from the hypertonic saline inhalation day from both the &quot;isotonic then hypertonic&quot; and the &quot;hypertonic than isotonic&quot; groups who had sufficient imaging data to allow for full analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Hypertonic Saline Inhalation</title>
            <description>Results from hypertonic saline inhalation day</description>
          </group>
        </group_list>
        <measure>
          <title>Mucociliary Clearance Rate After Hypertonic Saline Inhalation</title>
          <description>The clearance rate of Tc-SC after the inhalation of hypertonic saline</description>
          <population>This group includes data from the hypertonic saline inhalation day from both the &quot;isotonic then hypertonic&quot; and the &quot;hypertonic than isotonic&quot; groups who had sufficient imaging data to allow for full analysis.</population>
          <units>percent cleared / 80 minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.4" spread="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Comparing mucociliary clearance after isotonic saline inhalation to mucociliary clearance after hypertonic saline inhalation</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>alpha=0.05</non_inferiority_desc>
            <p_value>0.003</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the start of imaging day 1 to the end of imaging day 2</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Isotonic Saline Then Hypertonic Saline</title>
          <description>Subjects inhaled isotonic saline on study day 1 and hypertonic saline on study day 2</description>
        </group>
        <group group_id="E2">
          <title>Hypertonic Saline Then Isotonic Saline</title>
          <description>Subjects inhaled hypertonic saline on study day 1 and isotonic saline on study day 2</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>hospitalization</sub_title>
                <description>Subject was hospitalized between imaging days due to a problem not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tim Corcoran</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-624-8918</phone>
      <email>corcorante@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

